Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...